Humana (NYSE:HUM) Cut to Hold at Wall Street Zen

Humana (NYSE:HUM - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

Several other analysts have also recently commented on the company. Guggenheim initiated coverage on Humana in a research report on Wednesday, April 9th. They issued a "buy" rating and a $326.00 target price for the company. Mizuho lifted their price objective on Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a research report on Wednesday, April 9th. JPMorgan Chase & Co. reduced their price objective on Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a research report on Tuesday, February 18th. Truist Financial reduced their price objective on Humana from $325.00 to $305.00 and set a "hold" rating for the company in a research report on Monday, May 12th. Finally, Raymond James raised Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective for the company in a research report on Thursday, May 1st. Seventeen equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $284.24.

Humana Stock Performance

Shares of Humana stock opened at $234.87 on Friday. The stock has a market cap of $28.35 billion, a PE ratio of 23.60, a price-to-earnings-growth ratio of 2.05 and a beta of 0.43. The business has a fifty day simple moving average of $250.43 and a 200-day simple moving average of $262.89. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana has a 12 month low of $212.45 and a 12 month high of $406.46.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping the consensus estimate of $10.07 by $1.51. The business had revenue of $32.11 billion during the quarter, compared to analysts' expectations of $32 billion. Humana had a return on equity of 11.70% and a net margin of 1.02%. Humana's revenue was up 8.4% compared to the same quarter last year. During the same quarter last year, the firm posted $7.23 earnings per share. On average, sell-side analysts anticipate that Humana will post 16.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Pinnacle Wealth Management Advisory Group LLC lifted its holdings in shares of Humana by 3.6% during the fourth quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider's stock worth $272,000 after buying an additional 37 shares during the last quarter. Capital Advisors Ltd. LLC lifted its holdings in shares of Humana by 26.1% during the fourth quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider's stock worth $53,000 after buying an additional 43 shares during the last quarter. Retirement Planning Co of New England Inc. lifted its holdings in shares of Humana by 4.7% during the fourth quarter. Retirement Planning Co of New England Inc. now owns 966 shares of the insurance provider's stock worth $245,000 after buying an additional 43 shares during the last quarter. LFA Lugano Financial Advisors SA lifted its holdings in shares of Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after buying an additional 45 shares during the last quarter. Finally, Cary Street Partners Investment Advisory LLC increased its position in shares of Humana by 63.9% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock valued at $31,000 after purchasing an additional 46 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.